Peter Lawson
Stock Analyst at Barclays
(2.06)
# 2,901
Out of 5,182 analysts
102
Total ratings
41.57%
Success rate
-7.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $394 → $405 | $318.07 | +27.33% | 3 | Feb 27, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $23.78 | -7.49% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $96.92 | +4.21% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $33.60 | +19.05% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $12.80 | +95.31% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $2.07 | +44.93% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $43.61 | -8.28% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $3.48 | -13.79% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.39 | +43.88% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $8.94 | +11.86% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.78 | +5.82% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.80 | -53.13% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $31.46 | +65.29% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $9.78 | +12.47% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $10.81 | +48.01% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $5.29 | +183.55% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $22.74 | -38.43% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $2.05 | +46.34% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.43 | +109.79% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.56 | +156.41% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $146.23 | -58.97% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $16.40 | +3.66% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $17.04 | +81.92% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $26.39 | -50.74% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $4.51 | +10.86% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.89 | -28.43% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $132.86 | +174.73% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.07 | +69.93% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $100.35 | +348.43% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $3.57 | +1,160.50% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $57.69 | -22.00% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Overweight
Price Target: $394 → $405
Current: $318.07
Upside: +27.33%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $23.78
Upside: -7.49%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $96.92
Upside: +4.21%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $33.60
Upside: +19.05%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $12.80
Upside: +95.31%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $2.07
Upside: +44.93%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $43.61
Upside: -8.28%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $3.48
Upside: -13.79%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.39
Upside: +43.88%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $8.94
Upside: +11.86%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.78
Upside: +5.82%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.80
Upside: -53.13%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $31.46
Upside: +65.29%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $9.78
Upside: +12.47%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $10.81
Upside: +48.01%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $5.29
Upside: +183.55%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $22.74
Upside: -38.43%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $2.05
Upside: +46.34%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.43
Upside: +109.79%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.56
Upside: +156.41%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $146.23
Upside: -58.97%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $16.40
Upside: +3.66%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $17.04
Upside: +81.92%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $26.39
Upside: -50.74%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.51
Upside: +10.86%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.89
Upside: -28.43%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $132.86
Upside: +174.73%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.07
Upside: +69.93%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $100.35
Upside: +348.43%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $3.57
Upside: +1,160.50%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $57.69
Upside: -22.00%